Buprenorphine Induction in Persons With Opioid Use Disorder Hospitalized with Acute Hepatitis A

Devin A. Oller; Chase Thornton; Paul A. Nuzzo; Laura C. Fanucchi

doi:10.1097/ADM.0000000000000730

Buprenorphine Induction in Persons With Opioid Use Disorder Hospitalized with Acute Hepatitis A

Devin A. Oller
, Chase Thornton
, Paul A. Nuzzo
, Laura C. Fanucchi

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Background:It is not known whether buprenorphine/naloxone (bup/nx) can be safely initiated in hospitalized patients with acute hepatitis A infection. We assessed liver function and tolerability of bup/nx induction in patients with acute Hepatitis A Virus (HAV).Methods:Retrospective review of patients (N = 31) admitted to a tertiary care facility for acute HAV who were evaluated by an addiction medicine consultant.Results:No significant difference was seen in aspartate aminotransferase, alanine aminotransferase, total bilirubin, or INR trends in patients receiving bup/nx during hospitalization versus those not receiving bup/nx. Nausea was the most common reported symptom in patients receiving bup/nx.Discussion and Conclusions:With careful monitoring and induction dose adjustment, bup/nx can be administered to patients with acute HAV without hepatic encephalopathy. Similarly, patients on bup/nx before hospitalization should not have this medication held in the setting of acute HAV.Scientific Significance:This strategy may engage patients with acute HAV in treatment of OUD earlier and minimize disruptions in treatment.

Original language	English
Pages (from-to)	187-190
Number of pages	4
Journal	Journal of Addiction Medicine
Volume	15
Issue number	3
DOIs	https://doi.org/10.1097/ADM.0000000000000730
State	Published - May 1 2021

Bibliographical note

Publisher Copyright:
© 2022 Published by Wolters Kluwer on behalf of ASCRS and ESCRS Published by Wolters Kluwer Health, Inc.

Funding

The UK Addiction Consult and Education Service is funded by the Kentucky Opioid Response Effort, which is funded by the Substance Abuse and Mental Health Services Administration (SAMHSA) State Targeted Response to the Opioid Crisis (H79TI080264) and State Opioid Response (H79TI081704) grants awarded to the Kentucky Cabinet for Health and Family Services.

Funders	Funder number
Kentucky Cabinet for Health and Family Services
Kentucky Opioid Response Effort
State Opioid Response	H79TI081704
Substance Abuse and Mental Health Services Administration	H79TI080264

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

buprenorphine
hepatitis A
induction
opioid use disorder

ASJC Scopus subject areas

Psychiatry and Mental health
Pharmacology (medical)

Access to Document

10.1097/ADM.0000000000000730

Cite this

@article{aa49e80566824119a4f45c8ac3876ae3,

title = "Buprenorphine Induction in Persons With Opioid Use Disorder Hospitalized with Acute Hepatitis A",

abstract = "Background:It is not known whether buprenorphine/naloxone (bup/nx) can be safely initiated in hospitalized patients with acute hepatitis A infection. We assessed liver function and tolerability of bup/nx induction in patients with acute Hepatitis A Virus (HAV).Methods:Retrospective review of patients (N = 31) admitted to a tertiary care facility for acute HAV who were evaluated by an addiction medicine consultant.Results:No significant difference was seen in aspartate aminotransferase, alanine aminotransferase, total bilirubin, or INR trends in patients receiving bup/nx during hospitalization versus those not receiving bup/nx. Nausea was the most common reported symptom in patients receiving bup/nx.Discussion and Conclusions:With careful monitoring and induction dose adjustment, bup/nx can be administered to patients with acute HAV without hepatic encephalopathy. Similarly, patients on bup/nx before hospitalization should not have this medication held in the setting of acute HAV.Scientific Significance:This strategy may engage patients with acute HAV in treatment of OUD earlier and minimize disruptions in treatment.",

keywords = "buprenorphine, hepatitis A, induction, opioid use disorder",

author = "Oller, \{Devin A.\} and Chase Thornton and Nuzzo, \{Paul A.\} and Fanucchi, \{Laura C.\}",

note = "Publisher Copyright: {\textcopyright} 2022 Published by Wolters Kluwer on behalf of ASCRS and ESCRS Published by Wolters Kluwer Health, Inc.",

year = "2021",

month = may,

day = "1",

doi = "10.1097/ADM.0000000000000730",

language = "English",

volume = "15",

pages = "187--190",

number = "3",

}

TY - JOUR

T1 - Buprenorphine Induction in Persons With Opioid Use Disorder Hospitalized with Acute Hepatitis A

AU - Oller, Devin A.

AU - Thornton, Chase

AU - Nuzzo, Paul A.

AU - Fanucchi, Laura C.

PY - 2021/5/1

Y1 - 2021/5/1

N2 - Background:It is not known whether buprenorphine/naloxone (bup/nx) can be safely initiated in hospitalized patients with acute hepatitis A infection. We assessed liver function and tolerability of bup/nx induction in patients with acute Hepatitis A Virus (HAV).Methods:Retrospective review of patients (N = 31) admitted to a tertiary care facility for acute HAV who were evaluated by an addiction medicine consultant.Results:No significant difference was seen in aspartate aminotransferase, alanine aminotransferase, total bilirubin, or INR trends in patients receiving bup/nx during hospitalization versus those not receiving bup/nx. Nausea was the most common reported symptom in patients receiving bup/nx.Discussion and Conclusions:With careful monitoring and induction dose adjustment, bup/nx can be administered to patients with acute HAV without hepatic encephalopathy. Similarly, patients on bup/nx before hospitalization should not have this medication held in the setting of acute HAV.Scientific Significance:This strategy may engage patients with acute HAV in treatment of OUD earlier and minimize disruptions in treatment.

AB - Background:It is not known whether buprenorphine/naloxone (bup/nx) can be safely initiated in hospitalized patients with acute hepatitis A infection. We assessed liver function and tolerability of bup/nx induction in patients with acute Hepatitis A Virus (HAV).Methods:Retrospective review of patients (N = 31) admitted to a tertiary care facility for acute HAV who were evaluated by an addiction medicine consultant.Results:No significant difference was seen in aspartate aminotransferase, alanine aminotransferase, total bilirubin, or INR trends in patients receiving bup/nx during hospitalization versus those not receiving bup/nx. Nausea was the most common reported symptom in patients receiving bup/nx.Discussion and Conclusions:With careful monitoring and induction dose adjustment, bup/nx can be administered to patients with acute HAV without hepatic encephalopathy. Similarly, patients on bup/nx before hospitalization should not have this medication held in the setting of acute HAV.Scientific Significance:This strategy may engage patients with acute HAV in treatment of OUD earlier and minimize disruptions in treatment.

KW - buprenorphine

KW - hepatitis A

KW - induction

KW - opioid use disorder

UR - https://www.scopus.com/pages/publications/85107710917

UR - https://www.scopus.com/pages/publications/85107710917#tab=citedBy

U2 - 10.1097/ADM.0000000000000730

DO - 10.1097/ADM.0000000000000730

M3 - Article

C2 - 32909986

AN - SCOPUS:85107710917

SN - 1932-0620

VL - 15

SP - 187

EP - 190

JO - Journal of Addiction Medicine

JF - Journal of Addiction Medicine

IS - 3

ER -

Buprenorphine Induction in Persons With Opioid Use Disorder Hospitalized with Acute Hepatitis A

Abstract

Bibliographical note

Funding

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this